Page 48 - ARNM-1-1

Advances in Radiotherapy
& Nuclear Medicine CCRT plus nimotuzumab for cervical cancer

statistics. CA Cancer J Clin, 61: 69–90. Improved pelvic control and survival in RetroEMBRACE, a
multicenter cohort study. Radiother Oncol, 120: 428–433.
https://doi.org/10.3322/caac.20107
https://doi.org/10.1016/j.radonc.2016.03.011
3. Gaffney DK, Erickson-Wittmann BA, Jhingran A, et al.,
2011, ACR appropriateness criteria® on advanced cervical 13. Peiretti M, Zapardiel I, Zanagnolo V, et al., 2012,
cancer expert panel on radiation oncology-gynecology. Int Management of recurrent cervical cancer: A review of the
J Radiat Oncol Biol Phys, 81: 609–614. literature. Surg Oncol, 21: e59–e66.
4. Whitney CW, Sause W, Bundy BN, et al., 1999, Randomized https://doi.org/10.1016/j.suronc.2011.12.008
comparison of fluorouracil plus cisplatin versus hydroxyurea 14. Tewari KS, Sill MW, Penson RT, et al., 2017, Bevacizumab
as an adjunct to radiation therapy in stage ⅡB-ⅣA for advanced cervical cancer: Final overall survival and
carcinoma of the cervix with negative para-aortic lymph adverse event analysis of a randomised, controlled, open-
nodes: A Gynecologic Oncology Group and Southwest label, phase 3 trial (Gynecologic Oncology Group 240).
Oncology Group study. J Clin Oncol, 17: 1339–1348.
Lancet, 390: 1654–1663.
https://doi.org/10.1200/JCO.1999.17.5.1339
https://doi.org/10.1016/S0140-6736(17)31607-0
5. Rose PG, Bundy BN, Watkins EB, et al., 1999, Concurrent 15. Kim GE, Kim YB, Cho NH, et al., 2004, Synchronous
cisplatin-based radiotherapy and chemotherapy for locally coexpression of epidermal growth factor receptor and
advanced cervical cancer. N Engl J Med, 340: 1144–1153.
cyclooxygenase-2 in carcinomas of the uterine cervix: A
https://doi.org/10.1056/NEJM199904153401502 potential predictor of poor survival. Clin Cancer Res, 10:
1366–1374.
6. Morris M, Eifel PJ, Lu J, et al., 1999, Pelvic radiation with
concurrent chemotherapy compared with pelvic and para- https://doi.org/10.1158/1078-0432.ccr-0497-03
aortic radiation for high-risk cervical cancer. N Engl J Med, 16. Oh MJ, Choi JH, Kim IH, et al., 2000, Detection of epidermal
340: 1137–1143.
growth factor receptor in the serum of patients with cervical
https://doi.org/10.1056/NEJM199904153401501 carcinoma. Clin Cancer Res, 6: 4760–4763.
7. Keys HM, Bundy BN, Stehman FB, et al., 1999, Cisplatin, 17. Mathur SP, Mathur RS, Young RC, 2000, Cervical epidermal
radiation, and adjuvant hysterectomy compared with growth factor-receptor (EGF-R) and serum insulin-like
radiation and adjuvant hysterectomy for bulky stage IB growth factor II (IGF-II) levels are potential markers for
cervical carcinoma. N Engl J Med, 340: 1154–1161. cervical cancer. Am J Reprod Immunol, 44: 222–230.
https://doi.org/10.1056/NEJM199904153401503 https://doi.org/10.1111/j.8755-8920.2000.440406.x
8. Peters WA 3 , Liu PY, Barrett RJ 2 , et al., 2000, Concurrent 18. Kersemaekers AM, Fleuren GJ, Kenter GG, et al., 1999,
nd
rd
chemotherapy and pelvic radiation therapy compared with Oncogene alterations in carcinomas of the uterine cervix:
pelvic radiation therapy alone as adjuvant therapy after Overexpression of the epidermal growth factor receptor is
radical surgery in high-risk early-stage cancer of the cervix. associated with poor prognosis. Clin Cancer Res, 5: 577–586.
J Clin Oncol, 18: 1606–1613.
19. Noordhuis MG, Eijsink JJH, Ten Hoor KA, et al., 2009,
https://doi.org/10.1200/JCO.2000.18.8.1606 Expression of epidermal growth factor receptor (EGFR)
and activated EGFR predict poor response to (chemo)
9. Huang XD, Yi JL, Gao L, et al., 2007, Multi-center phase Ⅱ
clinical trial of humanized anti-epidermal factor receptor radiation and survival in cervical cancer. Clin Cancer Res,
monoclonal antibody h-R3 combined with radiotherapy 15: 7389–7397.
for locoregionally advanced nasopharyngeal carcinoma. https://doi.org/10.1158/1078-0432.CCR-09-1149
Zhonghua Zhong Liu Za Zhi, 29: 197–201.
20. Zhu Y, Luo J, Liu L, et al., 2012, Preoperative chemoradiation
10. Tsuchida Y, Therasse P, 2001, Response evaluation criteria in with nimotuzumab and capecitabine in patients with locally
solid tumors (RECIST): New guidelines. Med Pediatr Oncol, advanced rectal cancer: A phase II study. J Clin Oncol, 17:
37: 1–3. 634–641.
https://doi.org/10.1002/mpo.1154 https://doi.org/10.1200/jco.2012.30.15_suppl.e14049
11. Legge F, Chiantera V, Macchia G, et al., 2015, Clinical 21. Liang J, Mingyan E, Wu G, et al., 2013, Nimotuzumab
outcome of recurrent locally advanced cervical cancer combined with radiotherapy for esophageal cancer:
(LACC) submitted to primary multimodality therapies. Preliminary study of a Phase II clinical trial. Onco Targets
Gynecol Oncol, 138: 83–88. Ther, 6: 1589–1596.
https://doi.org/10.1016/j.ygyno.2015.04.035 https://doi.org/10.2147/OTT.S50945
12. Sturdza A, Ptter R, Fokdal LU, et al., 2016, Image guided 22. Zhai RP, Ying HM, Kong FF, et al., 2015, Experience with
brachytherapy in locally advanced cervical cancer: combination of nimotuzumab and intensity-modulated

Volume 1 Issue 1 (2023) 7 https://doi.org/10.36922/arnm.0408